Actinium Pharmaceuticals vs Longeveron
Longeveron is the larger business, with $1.2m of revenue in fiscal 2025 against $90,000 for Actinium Pharmaceuticals (13.3 times as much). Actinium Pharmaceuticals grew faster (11.1% against -49.9%). Longeveron kept more of each dollar of sales as profit: a net margin of -1893.6% against -37652.2%.
| Latest fiscal year | Actinium PharmaceuticalsATNM, 2025 | LongeveronLGVN, 2025 |
|---|---|---|
| Revenue | $90,000 | $1.2m |
| Revenue growth | 11.1% | -49.9% |
| Net income | −$33.9m | −$22.7m |
| Operating margin | — | -1942.2% |
| Net margin | -37652.2% | -1893.6% |
| Return on equity | -153.3% | -164.7% |
| Free cash flow | −$24.7m | −$18.9m |
| Cash | $48.0m | $4.7m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 25 | 37 |
| Market value | $44.8m | $55.5m |
| Price vs our value range | — | — |
| Moat score | — | 19 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |